Impact of genomic testing on urologists' treatment preference in favorable risk prostate cancer: A randomized trial.

Samuel CarbunaruZequn SunCordero McCallBernice OforiNorma MarshallHeidy WangMichael AbernLi LiuCourtney M P HollowellRoohollah SharifiPatricia VidalAndre Kajdacsy-BallaMarin SekosanKaren FerrerShoujin WuMarlene GallegosPeter H GannDaniel MoreiraLisa K SharpCarol E FerransAdam B Murphy

Published in: Cancer medicine (2023)

These findings demonstrate how obtaining prognostic biomarkers that predict negative outcomes before treatment decision-making might influence urologists' preference for recommending aggressive therapy in men eligible for active surveillance.

Keyphrases

prostate cancer
decision making
stem cells
radical prostatectomy
mesenchymal stem cells
adipose tissue
dna methylation
metabolic syndrome
insulin resistance
weight loss